Public health guidance on use of interferon-gamma release assays in support of TB diagnosis
This report sets out the evidence on IGRAs and their use in the diagnosis of latent and active tuberculosis.After reviewing all available evidence, the expert panel concluded that ‘IGRAs should not replace the standard diagnostic methods for diagnosing active TB.’ The panel also pointed out that IGRAs could provide an added value in certain clinical situations: patients with extrapulmonary TB, patients who test negative for acid-fast bacilli in sputum and/or negative for M. tuberculosis on culture, TB diagnosis in children, or in the differential diagnosis of infection with non-tuberculous mycobacteria.
Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA
5 Dec 2018 - The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. This Guidance in brief is based on the comprehensive guidance document which provides the evidence base for this guidance
Public health guidance on HIV, hepatitis B and C testing in the EU/EEA
23 Nov 2018 - This guidance aims to provide EU/EEA countries with an evidence-based framework to help develop, implement, monitor and evaluate their own national HBV, HCV and HIV testing guidelines and programmes.
Programmatic management of latent tuberculosis infection in the European Union
15 Oct 2018 - Programmatic management of latent tuberculosis infection (LTBI) is a key component of the global tuberculosis (TB) elimination strategy. This document provides evidence-based guidance for the implementation of programmatic management of LTBI in the European Union and European Economic Area (EU/EEA).